News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Treatment-experienced people news

Show

From To
Resistance
Poor levels of T-20 seen in semen of HIV-positive men

Concentrations of the fusion inhibitor T-20 (enfuvirtide, Fuzeon) in the genital tract are suboptimal, risking the development of resistant HIV, according to a small French

Published
09 September 2004
By
Michael Carter
Changing treatment
Keeping viral load below 20,000 copies/ml still beneficial, even after HIV rebound

Individuals with persistent, but modest HIV viral load (between 400 copies/ml and 20,000 copies/ml) are no more likely to die or develop new AIDS-defining illnesses

Published
07 September 2004
By
Michael Carter
Resistance
Second major study shows rise in drug resistance is not increasing AIDS or death risk

The development of resistance to antiretroviral drugs does not increase the risk of HIV disease progression or death, according to an American study published in

Published
05 August 2004
By
Liz Highleyman
Treatment-experienced people
Two-year data continue to show promise for T-20

In the second year of follow-up, patients injecting the fusion inhibitor enfuvirtide (T-20, Fuzeon) continue to exhibit viral suppression with no new adverse effects, according

Published
13 July 2004
By
Christopher Gadd
Treatment-experienced people
Boosted dual PI salvage regimen safe, effective but high pill burden an issue

A dual protease inhibitor regimen of saquinavir and amprenavir boosted with low-dose ritonavir appears safe and effective as salvage therapy, as long as therapeutic drug

Published
05 July 2004
By
Edwin J. Bernard
Resistance
Stopping NNRTIs in drug-resistant patients does not alter viral loads or CD4 cell counts

Withdrawal of non-nucleoside reverse transcriptase inhibitors (NNRTIs) from the antiretroviral drug combination of patients with resistance to this drug class does not lead to viral

Published
28 June 2004
By
Christopher Gadd
Resistance
Treatment failure due to drug resistance not a major cause of death

A Canadian study has found that treatment failure due to drug resistance did not significantly contribute to the mortality of people with HIV in British

Published
25 June 2004
By
Edwin J. Bernard
HIV treatment
Tipranavir access expanded, but doctors warned on double boosted PI regimens

Boehringer-Ingelheim has announced that its new experimental protease inhibitor tipranavir is to be made available to a wider number of patients in the United Kingdom. The

Published
15 June 2004
By
Keith Alcorn
Resistance
Boosted PIs superior to no PIs as salvage therapy in highly PI-experienced

A small Italian study comparing boosted protease inhibitor (PI) and PI-sparing salvage regimens in the highly PI-experienced has found the former superior in preserving CD4

Published
24 April 2004
By
Edwin J. Bernard
Treatment-experienced people
Gilead abandons research on salvage drug

Gilead Sciences today announced that it has decided to abandon its research programme to develop the experimental nucleoside analogue amdoxovir (DAPD). Rights to develop the

Published
28 January 2004
By
Keith Alcorn
← Prev1...910111213Next →

Filter by country